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Abstract
Background: Bone infections due to trauma and subsequent delayed or impaired fracture healing represent a
great challenge in orthopedics and trauma surgery. The prevalence of such bacterial infection-related types of
delayed non-union is high in complex fractures, particularly in open fractures with additional extensive soft-tissue
damage. The aim of this study was to establish a rat model of delayed osseous union secondary to bacterial osteitis
and investigate the impact of rhBMP-7 and rhBMP-2 on fracture healing in the situation of an ongoing infection.
Methods: After randomization to four groups 72 Sprague-Dawley rats underwent a transverse fracture of the
midshaft tibia stabilized by intramedullary titanium K-wires. Three groups received an intramedullary inoculation
with Staphylococcus aureus (103 colony-forming units) before stabilization and the group without bacteria
inoculation served as healing control. After 5 weeks, a second surgery was performed with irrigation of the
medullary canal and local rhBMP-7 and rhBMP-2 treatment whereas control group and infected control group
received sterile saline. After further 5 weeks rats were sacrificed and underwent biomechanical testing to assess the
mechanical stability of the fractured bone. Additional micro-CT analysis, histological, and histomorphometric
analysis were done to evaluate bone consolidation or delayed union, respectively, and to quantify callus formation
and the mineralized area of the callus.
Results: Biomechanical testing showed a significantly higher fracture torque in the non-infected control group and
the infected rhBMP-7- and rhBMP-2 group compared with the infected control group (p < 0.001). RhBMP-7 and
rhBMP-2 groups did not show statistically significant differences (p = 0.57). Histological findings supported improved
bone-healing after rhBMP treatment but quantitative micro-CT and histomorphometric results still showed
significantly more hypertrophic callus tissue in all three infected groups compared to the non-infected group.
Results from a semiquantitative bone-healing-score revealed best bone-healing in the non-infected control group.
The expected chronic infection was confirmed in all infected groups.
Conclusions: In delayed bone healing secondary to infection rhBMP treatment promotes bone healing with no
significant differences in the healing efficacy of rhBMP-2 and rhBMP-7 being noted. Further new therapeutic bone
substitutes should be analyzed with the present rat model for delayed osseous union secondary to bacterial osteitis.
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Background
Bacterial bone infections due to trauma with subsequent
delayed or impaired fracture healing are highly feared
complications in orthopedics and traumatology and rep-
resent a great challenge. Open fractures in particular ex-
hibit an incidence of osteitis as high as 55% [1]. Bacteria
colonizing implants can interfere with physiological
bone formation and remodeling mechanisms and lead to
a higher risk of impaired fracture healing [1, 2]. In most
cases, Staphylococcus aureus (S. aureus) is responsible
for infection. The bacterium can infiltrate osteoblasts,
builds biofilms and mutates into its small colony variants
form, all leading to a high antibiotic resistance [1, 3, 4].
Therefore currently available therapeutic options must
involve not only antibiotic treatment but also repeated
surgical debridement, potentially exacerbating extensive
bone defects [4]. Furthermore, prolonged treatment of
delayed fracture healing may have a profound effect on
both the medical and emotional condition of the patient
as well as his financial and professional security [5].
Bone morphogenetic proteins (BMPs), already estab-
lished as a useful addition to classic therapy in cases of
non-union and delayed fracture union, have not been
sufficiently investigated in infected fractures of the long
bones [6]. Only rhBMP-2 was evaluated on surgical in-
fections in a rabbit posterolateral lumbar fusion model
showing an insignificant trend toward improved fusion
rate and less mortality [7]. BMP-application is officially
not indicated in the situation of an infected non-union
of the long bones, because scientific data in the literature
is insufficient. Currently, BMPs can only be used
off-label in the situation of an infection.
BMPs are naturally responsible for the induction of
osteogenic differentiation of mesenchymal stem cells
and for angiogenesis and show limited expression during
delayed fracture healing [8–10]. Recombinant(rh)BMP-2
and rhBMP-7 have been proven to promote fracture
healing both in delayed fracture healing and non-union
animal models [11–14]. RhBMP-2 has shown high po-
tential in the treatment of open fractures in clinical tri-
als, leading to faster union establishment, lower
infection rate and lower number of surgeries needed
[15–17]. Similarly, rhBMP-7 could enhance the efficacy
and the treatment success of non-union in the combined
therapy with autologous cancellous bone [18].
The outcome of BMP-enhanced treatment of delayed
fracture healing in the situation of an ongoing low-grade
bone infection has not yet been sufficiently explored.
Therefore, the goal of this study was to investigate the
impact of rhBMP-7 and rhBMP-2 on fracture healing in
an animal model of delayed osseous union secondary to
chronic bacterial osteitis [19]. The hypothesis was that
rhBMP-7 and rhBMP-2 may improve bone healing in
the situation of an infection without significant
differences between both factors. Primary objective was
the fracture torque in biomechanical evaluations, sec-
ondary objectives were radiological and histological
outcome.
Methods
Preparation of bacterial inoculum
Bone infection in this study was induced by the bacter-
ium Staphylococcus aureus subsp. aureus Rosenbach
(ATCC® 49,230™) – a strain isolated from a patient with
chronic osteomyelitis and effectively used in the induc-
tion of bone infections before [20]. The needed amount
of 103 colony-forming units (CFU) had already been de-
termined in a previous study [19]. Bacterial cultivation
was performed according to the official product instruc-
tion, using Trypticase Soy Broth (TSB) for liquid cul-
tures and blood agar plates for plating (Becton,
Dickinson and Company, New Jersey, USA). All cultures
were handled under sterile conditions and incubated under
permanent oxygen supply at a temperature of 37 °C. Bac-
terial CFU counts on blood agar plates and spectrophoto-
metric measurements of liquid cultures were performed to
establish a calibration formula. An overnight culture
of S-. aureus in TSB, containing 103 CFU in 10 μl
was used for each surgery.
Animals and surgical procedure
All experiments were approved by the Animal Experi-
mentation Ethics Committee of Karlsruhe (35–9185.81/
G-171/11). 72 four-months old female Sprague Dawley
rats (Charles River Laboratories, Germany) with an aver-
age weight of 296 g were divided into four study groups
with 18 rats per group. Two of the groups were used as
controls with induction of a bone infection (+S. aureus)
or without infection (control). The animals in the two
other groups were used as study groups for the treat-
ment with rhBMP-7 (rhBMP-7 + S. aureus) or rhBMP-2
(rhBMP-2 + S. aureus).
Surgery preparation and follow-up
Prior to surgery, general anesthesia was performed by
a weight-adapted subcutaneous injection of medeto-
midine (Dorbene Vet 1 mg/ml), midazolam (Dormi-
cum 15 mg/3 ml) and fentanyl (Fentanyl – Janssen
0.05 mg/ml) after sedation with isoflurane in a sed-
ation box. Additional preparation for surgery included
shaving and disinfecting the right hind leg of the rat
and covering the animal body with sterile sheets.
Body temperature and anesthesia depth were tested
periodically during surgery. After completion of the
surgical procedure an anesthesia antidote mixture of
atipamezole (Antisedan 5 mg/ml), flumazenil (Fluma-
zenil Kabi 0.1 mg/ml) and naloxone (Naloxon Incresa
0,4 mg/ml) was injected. Clinical condition and body
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weight were controlled and a three-day post-operative
analgesic medication with buprenorphine (Temgesic)
was applied.
Fracture and infection model
During the first surgery all right tibiae were fractured
and a bacterial infection was induced in the infection
groups. A 5 mm incision through the skin and fasciae
medial to the ligamentum patellae was followed by dril-
ling a 1 mm hole through the cortical tibial bone at the
proximal metaphysis to access the medullar cavity.
Afterwards intramedullary reaming without irrigation
was performed using a 0.8 mm k-wire up to the distal
part of the medullar cavity. Tibia and fibula were then
fractured using an established fracture device [12, 19].
The right hind leg was placed on a metal plate and a
weight of 600 g was fixated 15 cm above the leg with a
removable pin. Removal of the pin resulted in a sudden
free fall of the weight and a consequent transverse frac-
ture of tibia and fibula (AO 42-A3) with a momentum
of 1.03 kg m/s. The bacterial inoculum of 103 CFU /
10 μl S. aureus was injected with a microliter syringe
into the medullar cavity of all tibiae in the infection
groups. All animals of the control group received the
same procedure using a sham liquid of 10 μl sterile
Tryptic Soy Broth (TSB). A closed reduction of the frac-
ture was performed with 0.8 mm k-wire ostheosynthesis.
The fascia and skin were sutured in a single-knot
technique.
Growth factor application
All animals received second surgery five weeks after the
first surgery. The skin incision was placed over the scar
of the previous suturing. The k-wire was carefully re-
moved and the medullar cavity was irrigated with sterile
saline. All animals of the control and infected control
group received an intramedullary injection of a control
fluid of 30 μl sterile saline at the fracture site. The other
infected animals received an intramedullary injection of
30 μg rhBMP-7 (1 μg/μl in sterile saline, Olympus, USA)
or 25 μg rhBMP-2 (1 μg/μl in sterile saline, Medtronic,
USA) respectively. A new k-wire was applied for osteo-
synthesis and the skin and fascia were sutured in a
single-knot technique.
Body weight and body temperature
Rectal body temperature was measured and body weight
was determined with a precision scale on post-operative
days 0, 7, 14, 35, 42 and 70. Further indications for local
or systemic infections were evaluated.
Sacrifice
The animals were sacrificed with CO2 in a sedation box.
The right tibiae of the hind legs were dissected under
sterile conditions. The entire soft tissue was removed
from bones.
Biomechanical testing
At the 10 weeks endpoint the intramedullary implants
were carefully removed (Control group: 9 samples; in-
fected control group: 9; rhBMP-7 group: 8; rhBMP-2
group: 7). Both tibiae were dissected free from soft tissue
for biomechanical torsional testing. After dissection of
the bones, the proximal and distal ends were placed into
two embedding molds (Technovit 4071, Heraeus Kulzer
GmbH, Germany) while using a fixture device to avoid
any preloading of the bones prior to testing. The lower
embedding mold was connected to a pivoted axis while
rotation of the upper mold was restrained (Fig. 1). A lin-
ear, constant rotation (10°/min) was applied by the bio-
mechanical testing device while the resultant torque was
recorded (8661–4500-V0200, Burster, Germany) until
bony fracture occurred. For biomechanical testing a
comparison with the contralateral tibiae of each animal
was done.
Micro-CT
The fractured tibiae of all animals were scanned with the
SkyScan 1076 in-vivo micro-computertomograph (Brucker
micro-CT, Belgium) at the endpoint (10 weeks after frac-
ture). The tibiae were scanned with an isotropic pixel size
of 18 μm and energy settings of 100 kV (voltage), 400 ms
(exposure time) and 100 μA (current) through a 1.0-mm
aluminium filter. Image reconstruction, including ring
artifact reduction (20/20), beam hardening correction
(30%) and smoothing (1/10) was performed using the
SkyScan NRecon software (v. 1.6.9.8, Brucker microCT,
Belgium).
Qualitative evaluation of the datasets was performed
by simultaneously viewing multiple orthogonal slices in
SkyScan DataViewer (v. 1.4, Brucker microCT, Belgium).
Additionally, new bone formation at the fracture site,
bridging of the fracture and bone remodeling were ana-
lyzed semi-quantitatively adopted from the scoring sys-
tem of Lane and Sandhu and given points from 0
(absent), 1 (25%), 2 (50%), 3 (75%) to 4 (100%) [21].
Hence, the highest possible score was 12 points. The
scoring system was used as “bone-healing-score”. The
modified score of An and Friedman was used to deter-
mine the grade of osteitis at the endpoint [22, 23]. The
score of An and Friedman is a radiographic scoring sys-
tem for assessing the development and progression of
osteomyelitis in a rabbit model. This score was used in
the study as “bone-infection-score”. Seven characteristic
parameters were analyzed: periosteal reaction (1), oste-
olysis (2), soft tissue swelling (3), deformity (4), general
impression (5), sequester formation (6) and spontaneous
fracture (7). For evaluation of the parameter 1 to 5, the
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tibia was divided into three regions of interest (ROI) –
proximal epiphysis, diaphysis and distal epiphysis, and a
score from 0 (absent), 1 (mild), 2 (moderate) to 3 (severe)
was given to each ROI. For parameters 6 and 7 the whole
tibia was graded with a score of either 0 (absent) or 1
(present). Therefore, the highest possible score was 47.
Bone morphometry of the 3D-dataset was performed
using the software CTAn (v. 1.13.2.1., Brucker microCT,
Belgium). The volume of interest (VOI) for each tibia
was defined as the bone area in between 3.5 mm prox-
imal and distal to the fracture line (400 slices) [24, 25].
The following parameters were used for bone morphom-
etry of the VOI for each animal at the endpoint after
10 weeks: tissue volume (TV), bone volume (BV) and
bone volume fraction (BV/TV).
Histology
The tibiae from each group were randomly harvested for
histological evaluation at the endpoint after 10 weeks as
previously described (Control group: 9 samples; infected
control group: 7; rhBMP-7 group: 6; rhBMP-2 group: 7)
[26]. Surrounding muscles and intramedullary implant
were carefully removed. After fixation for 2 days in 10%
normal buffered formaldehyde, dehydration was done in
ascending concentrations of ethanol and followed by
undecalcified embedding in methylmethacrylate (Techno-
vit 9100, Heraeus Kulzer GmbH, Germany). Longitudinal
sections in a sagittal plane were cut at 6 μm with a Leica
SM 2500 s microtome (Bensheim, Germany) with a 40°
stainless-steel knife. Different stains were used, including
von Kossa/Safranin-O, Masson Goldner and Gram stain
for microscopic visualization of mineralized bone, cartil-
age and S. aureus in the tissue and bone, respectively.
Evaluation was performed with a Leica DM-RB
microscope (Bensheim, Germany). Qualitative changes
were first evaluated in representative slides depicting the
fracture gap area. Further histological parameters were
measured with an image analysis system (Zeiss KS 400,
Germany) at a magnification of × 1.6 to calculate struc-
tural indices as described previously [26]. The region of
interest was defined at 3.5 mm proximally and distally to
the center of the fracture gap. The total diameter of the
callus was included in the ROI. For quantitative histomor-
phometric analysis, the area of the total callus (Total
callus area; [mm2]), the area of the periosteal callus (peri-
osteal callus area; [mm2]), and the mineralized periosteal
bone area of the periosteal total callus area (periosteal
bone area/periosteal total area; [%]) were measured and
compared between the four groups.
Statistics
Primary outcome measure was fracture torque in bio-
mechanical analysis. Secondary outcome measures were
the results from the bone-healing-score and the
bone-infection-score, and the results from quantitative
micro CT and histomorphometry. The sample size plan-
ning showed an effect size f of 0.82 and an actual power
of 0.878 with a sample size of 6 animals per group. A
final sample size of 9 animals per group was chosen to
compensate drop-outs. The post hoc power analysis pro-
vided an effect size f of 0.71 and an actual power of
0.918 for the biomechanical evaluations as the primary
end point. For descriptive statistics, mean and standard
deviation (SD) were calculated for continuous, median,
and interquartile ranges for ordinal variables. Group
comparisons were performed using one-way analysis of
variance (ANOVA) for independent samples. All tests
were two-sided and a p-value ≤0.05 was considered
Fig. 1 Biomechanical torsional testing machine with bone segment fixed in vertical direction by two embedding molds (detail view). A linear,
constant rotation speed of 10°/min was applied to measure the resultant torque needed to induce re-fracture
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significant. Statistical analysis was performed with SPSS
software (v. 22.0, IBM Corporation, USA).
Results
Body weight and body temperature
No significant differences of body weight and body
temperature were detected between the four groups.
Body weight moderately decreased in the four groups
during the first two weeks after surgery, but the animals
continuously gained weight afterwards reaching normal
weight again at the endpoint. Body temperature
remained stable in all groups during the 10 weeks
follow-up.
Drop-outs
Three animals died at the first and second operation, re-
spectively, due to complications with general anesthesia.
Two animals were sacrificed because of a postoperative
infected hematoma. Further 5 specimens had to be ex-
cluded due to technical problems during the preparation
of the tibiae.
Biomechanical testing
The K-wires could be removed easily in all cases, with
no differences detected between the groups. At the
contralateral non-fractured side, all groups did not show
statistically significant differences (p = 0.9). Average frac-
ture torques (Nm) was 0.213 +/− 0.022 Nm in the con-
trol group, 0.227 +/− 0.087 Nm in the infected control
group, 0.227 +/− 0.074 Nm in the rhBMP-7 group and
0.206 +/− 0.035 Nm in the rhBMP-2 group at the
non-fractured side. At the fractured side, Fracture tor-
ques (Nm) in the rhBMP-2, rhBMP-7, and control group
were significantly higher than in the infected control
group (p < 0.001) (Fig. 2). The differences between the
rhBMP-7 group and rhBMP-2 group were not
statistically significant (p = 0.6) (Fig. 2). The fractured
tibiae of the control group showed an average fracture
torque of 0.212 +/− 0.012 Nm, the rhBMP-7 group an
average fracture torque of 0.209 +/− 0.026 Nm and the
rhBMP-2 group a fracture torque of 0.203 +/− 0.018 Nm
compared to 0.147 +/− 0.019 Nm in the infected control
group (Fig. 2).
Micro-CT results
Micro-CT pictures of the non-infected control group
showed increased consolidation with complete bridging
of the fracture gap compared with both rhBMP-groups
and the infected control group at the endpoint (Fig. 3).
Compared to the non-infected control group, all infected
groups (infected control group (S. aureus), rhBMP-7
group (rhBMP-7 + S. aureus), rhBMP-2 group (rhBMP-2
+ S. aureus)) showed increased hypertrophic callus for-
mation. Most callus was visible in the infected control
group. Callus formation showed no differences between
the rhBMP-7 and the rhBMP-2 group (Fig. 3).
The non-infected control group presented a signifi-
cantly higher bone-healing-score representative for best
bone healing and bridging (p < 0.001) and a significantly
lower bone-infection-score compared to all other three
groups (p < 0.001). The scores of both rhBMP-groups
(rhBMP-7 + S. aureus, rhBMP-2 + S. aureus) did not
reach the level of the control group, but they showed
better results than the infected control group (S. aureus)
with fewer signs of osteitis, more bone formation and
enhanced bone remodeling (Fig. 4a and b).
Quantitative callus evaluation revealed that bone vol-
ume (BV) and tissue volume (TV) of the non-infected
control group were significantly lower than of the in-
fected groups (infected control group, rhBMP-7 group,
rhBMP-2 group) (Fig. 5a and b). Additionally, the
rhBMP-2 group and the rhBMP-7 group showed a
Fig. 2 Mechanical testing results of the tibiae: the re-fracture torque (Nm) is significantly lower in the infected control group than in the other
three groups at the endpoint. Lines with asterisk depict significant differences between groups (* p < 0.001)
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significantly lower bone volume fraction compared to
the control group. There were no statistically significant
differences between the infected control group and both
rhBMP-groups (Fig. 5c).
Histology
Qualitative evaluation of histological slides showed good
callus formation and progressed bone remodeling with
few connective tissue in the non-infected control group.
In the infected control group, more fibroblasts and cartil-
age were observed in the fracture region (Figs. 6 and 7: II).
Both rhBMP groups showed partially remodeled fractures
at the endpoint with only moderately remaining cartilage
or fibrous tissue (Figs. 6 and 7: III and IV). Gram stain
showed S. aureus in the orginal cortex and cancellous
bone in all specimens of the three infected groups (Fig. 8).
The bacteria were encapsulated in the cortex fragments. S.
aureus was not found in the newly formed woven bone in
all three infected groups. There were no significant differ-
ences between the three infected groups. Additionally, the
three infected groups showed a second cortex in the hist-
ology. Significant differences between these groups were
not detectable.
Histomorphometric analyses of the periosteal callus
area showed significant differences in the infected
control group (p = 0.009) and the rhBMP-2 group (p =
0.037) compared to non-infected controls (Fig. 9a). Ana-
lysis of callus composition still revealed significantly less
mineralized bone tissue in the periosteal callus in the
rhBMP-2 (p = 0.005) and rhBMP-7 group (p = 0.05) com-
pared to non-infected controls (Fig. 9b). Infected con-
trols and both rhBMP groups did not show significant
differences (p = 0.8 (rhBMP-7) and p = 0.3 (rhBMP-2)).
Discussion
In this study, we have evaluated the effect of recombin-
ant human bone morphogenetic proteins − 7 and − 2 for
the treatment of delayed osseous union secondary to
bacterial osteitis in our animal model using micro-CT
examinations, qualitative histology, histomorphometric
evaluations, and biomechanical investigations. To our
knowledge this is the first study, which compared re-
combinant human bone morphogenetic proteins − 7
and − 2 in an in vivo animal model of delayed osseous
union in the situation of an ongoing bacterial bone
infection.
We have chosen rhBMP-7 and -2 in our study setting,
because these growth factors have been established clin-
ically in the treatment of non-union [15, 27–29]. Gian-
noudis et al. [29] could show a synergistic effect of
Fig. 3 Micro computed tomography (micro-CT) of the right tibiae of Sprague-Dawley rats at the endpoint. Fracture, bacterial infection or sham
infection, and intramedullary stabilization with titanium Kirschner wires was performed 10 weeks before; application of rhBMP-7, rhBMP-2 or
sterile saline was done 5 weeks before analysis. Improved consolidation of the fracture gap is recognizable in the control group compared to the
three infected groups. Considerable differences in callus formation between both rhBMP groups were not detected
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autograft and bone morphogenetic protein − 7 in the
therapy of atrophic humeral, femoral and tibial
non-union with a healing rate of 100% in 45 patients.
Govender et al. [15] investigated rhBMP-2 in the treat-
ment of open tibial fractures and showed better fracture-
and wound-healing and reduced infection rate. Similar
effects have been described by others [30, 31]. Significant
differences in the effectiveness of both factors or syner-
gistic effects have not been described.
According to micro-CT-scans and histology, treatment
with rhBMPs was unable to achieve a complete union in
the situation of infection during the follow-up period, but
we could find positive effects on bone healing in biomech-
anical evaluations as well as in the semi-quantitative
bone-healing-score and in callus histology. Biomechanical
investigations and scoring of the micro-CT images re-
vealed significantly more stability and healing in the in-
fected rhBMP groups equal to non-infected controls if
compared to the infected control group. Thus, the find-
ings indicate that rhBMP treatment is possibly able to im-
prove bone healing in the setting of infection, although it
has no direct effect on the infection with S. aureus [32]. In
this regard, our investigations supported the results in the
literature [33, 34]. All infected groups, no matter if rhBMP
therapy was added or not showed significantly increased
mineralized callus (BV) and soft-tissue callus (TV), but a
significantly decreased bone volume fraction (BV/TV) in
quantitative micro-CT evaluation as well as larger perios-
teal callus areas and smaller mineralized periosteal bone
areas of the periosteal total callus area in histology. This
Fig. 4 Outcome of (a) the bone-healing-score adapted from Lane & Sandhu with a maximal score of 12 points and (b) the bone-infection-score
adapted from An & Friedman with seven characteristic parameters for a maximal score of 47 points. Both scores are significantly different
between the control group and the three infected groups. Lines with asterisk depict significant differences between groups (* p < 0.05)
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may be interpreted as a hypertrophic callus, explaining
less stability compared with the non-infected control
group. In agreement with other studies, Schmidmaier et
al. [28] and Bode et al. [35] postulated that an infection or
an instable fixation are the cause of a hypertrophic
non-union formation. They recommend repeated debride-
ments in case of infected, especially open fractures, with
stable osteosynthesis depending on the type of the fracture
to prevent non-union. In the present study, histology fur-
ther showed some qualitative differences of the callus. In
Fig. 5 Quantitative micro-CT evaluation of bone volume (mm3) (a), tissue volume (mm3) (b) and bone volume fraction (%) (c) of the four groups
at the endpoint. Lines with asterisk depict significant differences between groups (* p < 0.05)
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rhBMP specimens, we saw increased signs of fracture re-
modeling with only moderately remaining cartilage and fi-
brous tissue. These changes seemed less pronounced in
infected controls without rhBMP treatment. In contrast to
the study of Chen et al. [33, 34], which used a rat femur
model with a segmental chronically infected bone defect,
we were not able to achieve significantly more newly min-
eralized callus compared to infected controls in our ani-
mal model. A possible reason for this better
mineralization might be the additional antibiotic treat-
ment in the study of Chen et al.
As a limitation of our study, we did not analyze longer
follow-up times, so further effects might have been de-
tectable after the analyzed duration of 5 weeks after
rhBMP treatment. Furthermore, we were not able to
specifically identify or quantify the underlying mecha-
nisms for the increased stability, possibly due to tech-
nical limitations as the bone specimen had to be
collected, removed from soft tissue, further prepared
and fixed before cutting into 6 μm sections for
histological slides. Hence, semi-quantitative histological
assessment of the callus architecture was not possible.
Nevertheless, signs of partial fracture remodeling were
mainly found in rhBMP specimen contrary to more fi-
broblasts and remaining cartilage in infected controls.
Clinical studies such as the BESTT study (BMP-2
Evaluation in Surgery and Tibial Trauma) have pre-
sented both an accelerated healing process and a lower
infection rate after treatment with rhBMP-2 [15]. Simi-
larly successful results were obtained by a combined
two-step non-union therapy with rhBMP-7 after osteo-
myelitis [36]. However, it should be taken into consider-
ation that clinical routine therapy of bone infections also
involves debridement of necrotic bone, soft tissue man-
agement and antibiotic therapy [4, 37]. These procedures
lead to reduction of bacterial load and open the way for
osteoprogenitor cells from the periosteum, blood vessels
and soft tissue into the defect [38, 39]. Similar procedure
was used in the rhBMP-2 and rhBMP-7 studies in a rat
model of Chen et al. [33]. In the experimental setting of
Fig. 6 Overview and magnification (2.5×) of the fracture region stained with van Kossa/Safranin Orange (mineralized tissue: black; cartilage and fibrous
tissue: red): In the non-infected control group the callus is mineralized (*). No fracture healing is visible in the infected control group (+S. aureus) with
fibrous tissue and cartilage (**) filling the gap. Bone healing of the fracture is increased in both rhBMP groups with less fibrous tissue and less cartilage
filling. I) control group, II) infected control group (+S. aureus), III) rhBMP-7 group (rhBMP-7 + S. aureus) and IV) rhBMP-2 group (rhBMP-2 + S. aureus);
mineralized tissue: *; fibrous tissue and cartilage: **; muscles: mu
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Fig. 7 Magnifications (2.5× and 10×) of the fracture region stained with Masson Goldner (mineralized tissue: turquoise; cartilage and fibrous
tissue: green; nuclei: dark brown; muscles: brick-red): In the non-infected control group the callus is mineralized (*). No fracture healing is visible
in the infected control group (+S. aureus) with fibrous tissue and cartilage (**) filling the gap. Bone healing of the fracture is increased in both
rhBMP groups with less fibrous tissue and less cartilage filling. I) control group, II) infected control group (+S. aureus), III) rhBMP-7 group (rhBMP-7
+ S. aureus) and IV) rhBMP-2 group (rhBMP-2 + S. aureus); mineralized tissue: *; fibrous tissue and cartilage: **
Fig. 8 Bacterial infection visible in 5× and 40× magnification of the cortex region stained with Gram (bacteria: dark purple; mineralized tissue:
pink): S. aureus were found accumulated in the original cortex. Mineralized cortex: mc; bacteria: ba
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our study only intramedullary irrigation with sterile sa-
line, rhBMPs application and k-wire replacement were
performed, which will have maintained a high bacterial
burden in the bone. Most clinical cases of unsuccessful
non-union treatment reveal subclinical infection [36].
This clinical experience, together with the findings of
the current animal study suggest that an ongoing bone
infection will hamper bone healing with potentially re-
duced effectiveness of the rhBMPs. Further in-vivo stud-
ies might help to get further information on this topic.
RhBMP application in an animal model together with
differently concentrated bacterial suspensions and with-
out could be analyzed, to determine potential
bacterial-dose-dependent effects. Also adverse effects
have been described in the literature for rhBMP therapy
[40–43] but were not found in the present animal study
at least in the short term, as we did not find rhBMP as-
sociated side-effects or complications such as hetero-
topic ossifications or induction of neoplasms [42, 43].
Future studies should investigate later time-points
of bone healing in order to compare the biomechan-
ical, histological and radiological results with the
present study. Other growth factor application sys-
tems as well as other antibacterial or bone stimulating
substances and osteosynthesis techniques [44] could
also be analyzed with the present animal model con-
sidering their effectiveness in case of infection. The
long-term goal would be to establish a material or a
combination of materials and techniques that have
osteoinductive and osteoconductive but also anti-
microbial effects to provide bone healing within a
short operation and healing period.
Fig. 9 Histomorphometric evaluation of (a) periosteal callus area within the fracture gap (mm2) and (b) mineralized bone tissue in the periosteal
callus (%) between the groups at the endpoint. Lines with asterisk depict significant differences between groups (* p≤0.05)
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Conclusions
We could establish a rat model of delayed osseous union
secondary to experimental fracture and bone infection
with biomechanical, histological, and micro-CT evalu-
ation after treatment with rhBMP-2 and rhBMP-7 com-
pared to infected and non-infected controls. The
induced bone infection caused quantitatively more callus
tissue in all infected groups. In the infected control
group callus was biomechanically less stable and showed
less bridging. RhBMP treatment increased biomechan-
ical stability of the callus without significant differences
between rhBMP-2 and rhBMP-7. Our results demon-
strate that rhBMP treatment can improve bone-healing
in the situation of a chronic bone infection supporting
clinical use in complicated infected non-unions.
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